DTIL VS AKLI Stock Comparison

Performance

DTIL
10/100

DTIL returned -79.21% in the last 12 months. Based on SPY's performance of -20.66%, its performance is below average giving it a score of 10 of 100.

AKLI
10/100

AKLI returned -75.86% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

DTIL
68/100

DTIL had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 8.75 posts, 4.76 comments, and 13.29 likes per day.

AKLI

"Sentiment" not found for AKLI

Technicals

DTIL
14/100

DTIL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

AKLI
21/100

AKLI receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

DTIL
10/100

DTIL has missed earnings 5 times in the last 20 quarters.

AKLI
50/100

AKLI has missed earnings 2 times in the last 20 quarters.

Profit

DTIL
10/100

Out of the last 20 quarters, DTIL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

AKLI
12/100

Out of the last 11 quarters, AKLI has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

DTIL
32/100

DTIL has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.

AKLI
46/100

AKLI has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Precision BioSciences, Inc. Common Stock Summary

Nasdaq / DTIL

Healthcare

Biotechnology

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Akili, Inc. Common Stock Summary

Nasdaq / AKLI

Healthcare

Medical - Healthcare Information Services

Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

Power up your portfolio